Results 11 to 20 of about 1,671,061 (305)
Metabolic Implications of Immune Checkpoint Proteins in Cancer
Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response.
Elizabeth R. Stirling +5 more
doaj +1 more source
The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity
Immune checkpoint inhibitors, medications that boost host immune response to tumor cells, are now at the forefront of anti-cancer therapy. While efficacious in the treatment of patients with advanced cancer, immune checkpoint inhibitors can lead to ...
Emily M. Moss +2 more
doaj +1 more source
Immune checkpoint inhibitors in malignancy [PDF]
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire +2 more sources
Immune checkpoint inhibitors have revolutionized immunotherapy against various cancers over the last decade. The use of checkpoint inhibitors results in remarkable re-activation of patients’ immune system, but is also associated with significant adverse ...
Victoria C. Brom +3 more
doaj +1 more source
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Allan Andersson Lima Pereira +9 more
core +1 more source
Archetypes of checkpoint-responsive immunity
Responsiveness to immune checkpoint blockade (ICB) therapy in cancer is currently predicted by disparate individual measures - with varying degrees of accuracy - including tumor mutation burden, tumor-infiltrating T cell densities, dendritic cell frequencies, and the expression of checkpoint ligands.
Kwok, Im +4 more
openaire +3 more sources
This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production ...
Rasmus Strøm Risbjerg +3 more
doaj +1 more source
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to ...
Remy Thomas +4 more
doaj +1 more source
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
The clinical success of immune checkpoint inhibitors has highlighted the central role of the immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer immunity and are now the standard of care in a number of malignancies.
Xiuting Liu +2 more
doaj +1 more source
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian +5 more
doaj +1 more source

